REPROCELL USA株式会社
基本情報
- 所在地
- 米国メリーランド州ベルトスビル
- 社長
- 横山千香文
- 従業員数(単独)
- 従業員数(連結)
- 開始日
- 2003-02-01
- 終了日
サイト
事業内容
関連会社
| 会社名 | Group | 親会社 | 子会社 | 得意先 | 仕入先 | 業務提携 | 銀行等 | 株主等 |
|---|---|---|---|---|---|---|---|---|
|
|
||||||||
|
|
||||||||
|
|
||||||||
| Maryland Stem Cell Research Fund | ||||||||
|
|
||||||||
|
|
||||||||
|
|
||||||||
| panCELLa/Implant Therapeutics |
関連図
沿革
ニュース
REPROCELL Expands iPSC in China
REPROCELL Inc. announced a strategic collaboration with WEIPU Biotechnology Co., Ltd. in Suzhou, China, to provide cell therapy developers with access to StemRNA™ Clinical iPSC technologies and iPSC‑derived mesenchymal stem cell seed and master cell banks, supporting high‑quality clinical starting materials and complementary biological testing services.
REPROCELL Secures MSCRF Award
REPROCELL (TYO: 4978) announced that it has received a competitive Commercialization Award from the Maryland Stem Cell Research Fund (MSCRF). The award will fund the development of clinical‑grade, hypoimmune induced pluripotent stem cell (iPSC) seed stocks using REPROCELL’s StemRNA™ reprogramming platform combined with StemEdit technology.
REPROCELL Co-Authors IBD AI Study
REPROCELL Europe scientists co‑authored a Scientific Reports paper showing that biomedical foundation models combined with multi‑omics feature engineering can enhance drug‑response predictions for inflammatory bowel disease patients. The study, which involved partners from IBM Research Europe and the STFC Hartree Centre, highlights the potential of AI‑driven approaches in personalized IBD treatment.
REPROCELL USA Opens GMP Cell Facility
REPROCELL USA Inc. announced the opening of a new GMP‑compliant cell culture facility on April 7, 2026, enhancing its regenerative medicine manufacturing capabilities. The ceremony was attended by President and Global CEO Dr. Yokoyama, CEO Mr. Rama Modali, and Maryland Lieutenant Governor Aruna Miller. The company continues to produce clinical‑grade iPSCs, including its proprietary StemRNA™ Clinical iPSC Seed Clones, in compliance with FDA, EMA, and PMDA standards.
REPROCELL Launches GMP MCB for iPSCs
REPROCELL has launched a US FDA‑compliant GMP Master Cell Bank manufacturing service for human induced pluripotent stem cells (iPSCs). The service, based at its Beltsville, Maryland facility, offers an end‑to‑end workflow that includes StemRNA™ clinical seed production, StemEdit gene‑editing, and GMP MCB production.
REPROCELL Adds BioThrust ComfyCell Incu
REPROCELL announced the addition of the BioThrust™ ComfyCell Incu bioreactor platform to its product catalogue, enhancing its offerings for advanced human cell culture and stem cell research. The 300 mL single‑use system is designed for intensified and scalable cultivation of sensitive cells. As a licensed worldwide distributor, REPROCELL now provides researchers with access to this innovative technology.
REPROCELL Launches StemEdit Gene Editing
REPROCELL announced the commercial launch of StemEdit, its clinical gene editing services and new gene‑edited iPSC product lines that use the AI‑designed OpenCRISPR‑1™ system licensed from Profluent. StemEdit combines REPROCELL’s proprietary clinical gene‑editing technology with StemRNA™ Clinical iPSC Seed Clones, providing GMP‑aligned, traceable, regulatory‑compliant solutions ready for immediate use.